Strengthen the domestic pharmaceutical supply chain and promote American-made medicines.

Strengthening our domestic pharmaceutical supply chain so that we are less dependent on adversarial countries, like China, for essential medicines is a national security priority. We must promote American-made medicines.

Commits to strengthening domestic drug supply chains and encouraging U.S.-made medicines.

Health Care : U.S. Representative Buddy Carter
primary · campaign_site · model gpt-5.4-mini

Included in this funding package are Rep. Carter’s policies to: Prohibit PBM compensation in Medicare Part D from being tied to the manufacturer’s list price of a drug in an effort to reduce drug prices and save money for taxpayers. Promote price transparency for prescription drugs purchased by employer health plans... Require the Centers for Medicare & Medicaid Services (CMS) to define and enforce “reasonable and relevant” Medicare Part D contract terms... Promote transparency by allowing CMS to track payment trends to pharmacies and pharmacy inclusion in PBM networks

Carter backs PBM reforms that increase transparency and lower prescription drug costs.

Carter celebrates passage of his key PBM reforms to lower costs for patients : U.S. Representative Buddy Carter
primary · press_release · model gpt-5.4-mini

Rep. Earl L. “Buddy” Carter introduced the Growing America’s Pharmaceutical Supply Act, saying it would alleviate drug shortages by giving outsourcing facilities more certainty to produce medications and increase domestic drug development.

Recent official House statement showing Carter actively pursued legislation aimed at strengthening domestic drug production and supply resilience.

partial same_term A for effort

Carter introduces bill incentivizing domestic production to alleviate drug shortages
secondary · model gpt-5.4-mini · confidence 94%

Congress.gov shows H.R. 7528 was introduced by Rep. Carter and referred to the House Committee on Energy and Commerce; the bill remains at the introduced stage with no further action listed.

Official legislative status confirms Carter filed a supply-chain bill, but it has not advanced beyond introduction and committee referral.

partial same_term A for effort

Actions - H.R.7528 - 119th Congress (2025-2026)
secondary · model gpt-5.4-mini · confidence 97%

The White House proclaimed that pharmaceutical imports threaten national security and imposed tariffs/negotiation steps intended to shift production onshore and strengthen domestic pharmaceutical supply chains.

Executive action within the lookback window materially advances the domestic-manufacturing direction of Carter’s stated goal, though it is not a Carter-authored delivery and does not fully resolve the claim.

partial same_term

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States
secondary · model gpt-5.4-mini · confidence 84%